Tag Archives: Warren Woessner

Bayer v. Lupin – Patenting The Label Redux

Posted on February 28, 2012 by Warren Woessner

In my post of January 13, 2011, I discussed AstraZeneca LP v. Apotex, a Fed. Cir. decision in which AZ argued successfully that the proposed  Apotex labeling for an anti-asthma drug would induce infringement if the generic were marketed with … Continue reading →

Posted in Hatch-Waxman | Tagged , , , , , , , , , , , | Leave a comment

Top Apps For Lawyers

Posted on February 24, 2012 by Warren Woessner

Attorney At Work, a website that provides “one really good idea every day” recently published a list of the top iPhone and iPad apps for lawyers. Joan Friedman wrote: If you’re a smartphone or tablet user—veteran or newbie—you know there’s … Continue reading →

Posted in Miscellaneous | Tagged , , , , , | Leave a comment

Supreme Court Declines To Review “New And Improved” Written Description Requirement

Posted on February 22, 2012 by Warren Woessner

On Tuesday, the Supreme Court denied Centocor’s (now “Janssen”) petition for cert. and so let stand a ruling that Centocor’s patents on humanized monoclonal antibodies (covering Abbott’s Humira) are invalid for failure to meet the written description requirement (WDR) of … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , , , | Leave a comment

Griffith Hack And Ambercite Map The Alzheimer’s Disease Patent Landscape

Posted on February 17, 2012 by Warren Woessner

Although I received this report: “Clearing The Fog; Patenting Trends For The Treatment Of Alzheimer’s Disease” both directly and from a number of colleagues, I won’t presume that it has been widely read, but it should be. (A copy of the … Continue reading →

Posted in Miscellaneous | Tagged , , , , , | Leave a comment